Vascular endothelial growth factor A (VEGFA) is widely accepted as the most potent stimulator of tumor angiogenesis [21], with anti-VEGFA therapies revealing promising outcomes in pre-clinical trials [22, 23]. The gene discussed is VEGFA; the disease is neoplasm.